

Lonza Ltd Muenchensteinerstrasse 38 CH-4002 Basel, Switzerland +41 61 316 81 11 +41 61 316 91 11 media@lonza.com



News Release

Lonza's CHRO Elected to Board of Advance Women in Swiss Business

Basel, Switzerland, 27 June 2017 – Fridtjof Helemann, Chief Human Resources Officer (CHRO) for <u>Lonza</u>, has been elected to the Board of <u>Advance Women in Swiss Business</u>. The mission of this non-profit association is to actively increase the share of women in leading positions in Swiss companies on an ongoing basis.

Founded in September 2013 by 10 major multinational firms doing business in Switzerland, the networking group has expanded six-fold in the last years as it strives to support women in the workplace.

"Lonza holds to the belief echoed by Advance Women that gender equality and inclusion are a competitive advantage in business," said Fridtjof Helemann, Lonza's Chief Human Resources Officer. "Membership in this organization will help us to discover new ways of balancing our gender mix and at the same time give us the opportunity to share our own positive experiences with other Swiss companies."

About Lonza

Lonza is one of the world's leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. It harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life.

Not only is Lonza a custom manufacturer and developer, the company also offers services and products ranging from active pharmaceutical ingredients to drinking water sanitizers, from nutritional and personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with approximately 40 major manufacturing and R&D facilities and more than 10,000 full-time employees worldwide. The company generated sales of CHF 4.13 billion in 2016 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Further information can be found at www.lonza.com.

Lonza Contact Details
Dirk Oehlers, Head Investor Relations
Lonza Group Ltd
Tel +41 61 316 8540
dirk.oehlers@lonza.com

Dominik Werner, Head Corporate Communications Lonza Group Ltd Tel +41 61 316 8798 dominik.werner@lonza.com

Constance Ward, Head External Communications Lonza Group Ltd Tel +41 61 316 8840 constance.ward@lonza.com

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.